Answers are grounded in this paper and cite their sources.
Substantial reductions in childhood pertussis have been achieved in the developed world through use of effective vaccines in an evidenced-based fashion. However, pertussis control is complicated by limited persistence of immunity after immunization and infection [1, 2], unrecognized disease and asymptomatic carriage contributing to transmission [3, 4], and resurgence of recognized disease in adolescents and adults in many developed countries [5, 6]. Infants aged <6 months—too young to have completed the primary series of pediatric diphtheria-tetanus–acellular pertussis (DTaP) vaccine—are at high risk for infection with Bordetella pertussis and for severe complications. Low levels and rapid decay of maternal antibodies in infants results in limited passive immunity in the first year of life [1, 7]. In the United States, 83% of pertussis-related deaths occur in infants aged <3 months [8]. The increase in the rate of pertussis among adolescents and adults has put more young infants at risk for exposure to B. pertussis. Over the past 30 years there has been growing evidence of risk for transmission of pertussis to infants from family and caregivers [9]. Despite lack of an identified source for 40%–70% of infant pertussis cases, household contacts have accounted for the majority of implicated transmissions to infants [4, 10, 11], with some differences in observed proportions of parents and siblings as sources. The paper by de Greeff et al [12] in this issue of Clinical Infectious Diseases reinforces these observations and highlights some salient points regarding acquisition and severity of pertussis in young infants. Source cases were implicated for 84% of 164 households of index cases with full testing of contacts. Mothers accounted for 38% of implicated transmissions, fathers for 17%, and siblings for 41%. The severity of pertussis in the hospitalized index case infants was apparent in the symptoms, complications, and treatment required. Among siblings who had received at least 4 doses of pertussis-containing vaccine within 3 years, 69% had laboratory-confirmed pertussis infection, with atypical or asymptomatic pertussis in 29% of those who received whole-cell vaccine and 61% of those who received acellular pertussis vaccine. It as been proposed that selective pressure of immunity derived from the whole-cell vaccine used in the Netherlands prior to the introduction of the acellular vaccine caused genetic drift in circulating B. pertussis with reduced immune recognition, decreased vaccine efficacy, and reemergence of pertussis [13]. Although pertussis can be prevented through isolation and antibiotic prophylaxis, the most direct way to prevent pertussis in infants is to immunize them on time with DTaP vaccine. Consideration is even being given to a birth dose of pertussis vaccine, but interference from maternal antibody may reduce efficacy [14]. The licensure of 2 tetanus-diphtheria–acellular pertussis (Tdap) vaccines for adolescents and adults in 2005 (Boostrix [GlaxoSmithKline] and Adacel [Sanofi Pasteur]; as of 2009, licensed for use in persons aged 10–64 and 11–64 years, respectively) offered the opportunity not only to reduce the substantial impact of pertussis on adolescents [15], but also prevent pertussis in those who may expose infants (including health care providers). The US Advisory Committee on Immunization Practices (ACIP) has recommended routine administration of Tdap to adolescents aged 11–18 years, adults (in place of the recommended decennial dose of tetanus-diphtheria [Td] vaccine), health care workers, and women before conception and after birth who have not received Td vaccine in as short as a 2-year interval. However, the ACIP stopped short of recommending routine use of Tdap in pregnant women, because the safety and efficacy of Tdap in pregnancy has not been established, despite studies suggesting safety [8]. A precautionary “consideration” for its use in pregnant women was suggested. The theoretical interference with the infant's immune response to DTaP vaccine in the first 6 months of life as a result of maternal vaccination has also been a concern. The Infectious Diseases Society of America endorses the ACIP recommendations [16], as does the American Congress of Obstetricians and Gynecologists, although the American Congress of Obstetricians and Gynecologists suggests vaccinating pregnant women if the risk of exposure is felt to be higher than undefined risks of the vaccine [17], and the American Academy of Pediatrics recommends the use of Tdap for pregnant adolescents in the same way as for nonpregnant adolescents [18]. In all cases, if administered to pregnant women, counseling and use in the second or third trimester is recommended. Effective immunization of potential parents—in fact, all adults—against pertussis would protect infants. Assuring the full vaccination of siblings of newborns, with adherence to a recommended 5th pre-school dose of DTaP (which was not fully implemented in the Netherlands at the time of the study by de Greeff et al [12]) is also beneficial [19]. However, a possible higher likelihood of atypical pertussis with the use of DTaP versus whole cell pertussis vaccine (perhaps reflecting greater effectiveness of the DTaP in preventing more severe symptoms, if not infection, or reflecting a less protective whole-cell vaccine used in the Netherlands) was observed by de Greeff and colleagues. Although the diagnosis of typical pertussis is all too often missed or delayed, atypical pertussis may not even raise suspicion of pertussis until other cases in the household appear, making antibiotic treatment to prevent transmission less effective. Although pertussis varies in incidence through a 3–5-year cycle, it appears that there is a real trend in decreasing incidence of pertussis, especially among adolescents, concurrent with increasing use of Tdap (Massachusetts Department of Public Health, unpublished data) [20]. Reduction of the adolescent reservoir reduces exposure and infection of younger children, as well as infants. If Tdap also prevents asymptomatic B. pertussis infection in adolescents and adults, herd immunity could further reduce risk for exposure of infants [21], although such herd immunity has not yet been demonstrated to result from Tdap use. All children should receive the recommended doses of pertussis vaccine on time, and everyone who comes in contact with young infants and is eligible for a recommended dose of Tdap should receive it—especially new parents, other household contacts of newborns, and health care workers. This is referred to as “cocooning” the infant, and mathematical modeling suggests that it could be an effective strategy to prevent infant pertussis [22]. In 2008, it was estimated that only 41% of 13–17-year-old persons in the United States had received a dose of Tdap after the age of 10 years, and <3% of adults aged 18–64 years in 2007 reported receiving a dose of Tdap in the previous 2 years [23, 24]. Not having Tdap at hand, lack of routine patient visits, and concern about the interval since the most recent dose of Td have been identified as some of the barriers to both adolescent and adult Tdap immunization [25, 26]. Obstetricians have a generally positive disposition toward using Tdap in postpartum women and even in pregnant women [27], but difficulties implementing effective systems, such as opt-out standing orders for maternity services, and concern about the timing of the last Td vaccine dose are barriers, as are patient concerns about the safety of the vaccine or about receiving any vaccine during pregnancy. There is resistance to pertussis immunization among health care workers [28], and even among health care workers who state a willingness to receive Tdap, actual immunization rates are low [29]. There have been some structural and innovative approaches to improving vaccination of adolescents and adults with Tdap that would benefit protection of infants, such as routine postpartum orders [30] and offering Tdap vaccine to new parents during pediatric well baby visits [31]. Success in accomplishing the goal of reducing infant pertussis will require serious commitment and new approaches. If it does takes a village to raise a child, then that village should be fully immunized against pertussis. We thank Larry Madoff for providing valuable advice and review. Potential conflicts of interest. A.D. and S.M.L.: no conflicts.
No takes yet. Share an insight, caveat, or question.
DeMaria et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: